Routine use of a spike‐in DNA in‐process control for foetal RHD genotyping: Testing the real‐world effectiveness of this ‘canary’

Documenti analoghi

• Real‐world performance of a clinical droplet digital polymerase chain reaction assay for non‐invasive foetal blood group and platelet antigen genotyping of alloimmunized pregnant women with antibodies directed against RhD, RhE, Rhc, RhC, K1, HPA‐1a or HPA‐5b: A 1‐year experience
  di: Camilla Calandrini, et al.
  Pubblicazione: (2024)
• Screening of pregnant women for foetal neonatal alloimmune thrombocytopenia: A cost–utility analysis
  di: Thijs W. de Vos, et al.
  Pubblicazione: (2024)
• Cost‐effectiveness of cEK ‐preventive matched transfusion strategies for female transfusion recipients to prevent haemolytic disease of the foetus and newborn in the Dutch healthcare setting
  di: Jessie S. Luken, et al.
  Pubblicazione: (2026)
• Unifying serological testing for cold agglutinins
  di: Marit Jalink, et al.
  Pubblicazione: (2025)
• Laboratory approach for vaccine‐induced thrombotic thrombocytopenia diagnosis in the Netherlands
  di: Romy T. Meier, et al.
  Pubblicazione: (2024)